Cassava Sciences to Present Interim Simufilam Data From Open-Label Alzheimer's Study in July
Cassava Sciences () said Monday it plans to provide interim data in late July from the first 50 patients to complete nine months on its experimental oral Alzheimer's treatment.
The company plans to present an interim analysis on safety and cognition, along with biomarkers data, from its ongoing open-label drug study of simufilam the week of July 26-30 at the Alzheimer's Association International Conference in Denver, Cassava said.
In the second half of 2021 the company plan to launch a phase 3 program for simufilam consisting of two double-blind, randomized, placebo-controlled studies in patients with mild-to-moderate Alzheimer's disease, Cassava said.
The company said it had approximately $282 million in cash as of March 31, providing it with "a financial runway" to support the phase 3 clinical development program of simufilam. Net cash use for operations for full-year 2021 is still expected to be approximately $20 million to $25 million, according to the company's statement.
Cassava also said it will present in Denver next month a clinical dataset from a study of SavaDx, an investigational candidate to detect Alzheimer's disease with a blood test.
Shares were up 7% in midday trading.
Price: 85.35, Change: +5.70, Percent Change: +7.16